GYRE (Gyre Therapeutics) Float Percentage Of Total Shares Outstanding: 31.57% (As of Jul. 01, 2026)


GYRE Gyre Therapeutics Inc GYRE
39 GF Score
Price $6.50
GF Value $9.82
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics Float Percentage Of Total Shares Outstanding?

Gyre Therapeutics GYRE -1.37% 39 Float Percentage Of Total Shares Outstanding is 31.57% as of Jul. 01, 2026. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.82 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Gyre Therapeutics's float shares is 35.19 Mil. Gyre Therapeutics's total shares outstanding is 111.49 Mil. Gyre Therapeutics's float percentage of total shares outstanding is 31.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Gyre Therapeutics's Insider Ownership is 0.74%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Gyre Therapeutics's Institutional Ownership is 4.13%.

GYRE
39GF Score
Gyre Therapeutics Inc GYRE
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gyre Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Gyre Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=35.19/111.49
=31.57%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 31.57% mean?
Gyre Therapeutics (GYRE) has a Float Percentage Of Total Shares Outstanding of 31.57% as of Jul. 01, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Gyre Therapeutics and its competitors.
Is Gyre Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Gyre Therapeutics' current Float Percentage Of Total Shares Outstanding is 31.57%. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Float Percentage Of Total Shares Outstanding compare to RLMD and ACRS?
Gyre Therapeutics' Float Percentage Of Total Shares Outstanding of 31.57% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current Float Percentage Of Total Shares Outstanding is 31.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.82, compared to a current price of $6.50 — trading 33.8% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 31.57%. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Float Percentage Of Total Shares Outstanding is 31.57% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $6.50 is trading 33.8% below its estimated GF Value™ of $9.82. GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.

Key valuation signals for GYRE:

  • Float Percentage Of Total Shares Outstanding: 31.57%
  • GF Value™: $9.82 vs. price of $6.50 (33.8% below fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score

Get the complete analysis for GYRE

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.50
Price
$9.82
GF Value